Primary resistance (PR) of mycobacterium tuberculosis (MBT) to antimicrobial drugs (AMBD) in patients (P) with destructive pulmonary tuberculosis Source: Eur Respir J 2004; 24: Suppl. 48, 655s Year: 2004
Herpes-simplex virus (HSV) in pulmonary tuberculosis (TB) with delayed response to treatment in patients from radio-nuclide contaminated areas (RNCA) Source: Eur Respir J 2002; 20: Suppl. 38, 558s Year: 2002
High rate of hepatitis due to treatment with pyrazinamide (PYR) and ethambutol (EMB) for latent tuberculosis infection (LTBI) in subjects exposed to MDR-TB Source: Annual Congress 2005 - Management of tuberculosis pulmonary, extrapulmonary peculiarities Year: 2005
Bio-Chip (BCh) technology for diagnostics of multidrug resistance (DR) of mycobacterium tuberculosis (MBT) from patients with disseminated tuberculosis (DT) Source: Annual Congress 2008 - Genetics, immunology and microbiology of tuberculosis Year: 2008
Tuberculosis (TB) relapse rate among patients treated with moxifloxacin (m) or ethambutol (E) in the intensive phase of therapy Source: Annual Congress 2009 - Treatment of tuberculosis at times of emerging drug resistance Year: 2009
Efficacy evaluation, time estimates for method of bronchial valve closure (BVC) in the treatment of patients with double infections of immunodeficiency virus / tuberculosis (HI virus/TB) Source: International Congress 2019 – Interventional pulmonology: current pleural practice Year: 2019
Interferon-γ release assays (IGRA) vs. tuberculin skin testing (TST) for detecting latent tuberculosis infection (LTBI) in chronic hemodialysis (CH) patients Source: Annual Congress 2008 - New tools in tuberculosis diagnosis Year: 2008
The efficiency of the treatment of the patients with culture-positive pulmonary tuberculosis (CPPTB) in Gdannsk, Poland in 1995 and 2000 Source: Annual Congress 2005 - Epidemiology and control of tuberculosis and LTBI Year: 2005
Efficacy of combined therapy in severe community-acquired pneumonia (CAP) with efferent detoxication methods (EDM) vs. standard therapy by antibiotics (STA) Source: Eur Respir J 2005; 26: Suppl. 49, 638s Year: 2005
The role of quantiferon tuberculosis gold test (Q) in diagnosing active tuberculosis (TB) and latent tuberculosis infection (LTI) in children Source: Annual Congress 2008 - New tests and methods to diagnose tuberculosis infection and disease and to monitor treatment Year: 2008
Long term plasma rifampicin (R) concentrations in AIDS patients with tuberculosis (TB) under HAART therapy Source: Eur Respir J 2003; 22: Suppl. 45, 40s Year: 2003
High completion rates with directly observed preventive treatment (DOPT) of latent tuberculosis infection (LTBI) in Ethiopian immigrants (EI) to Israel Source: Annual Congress 2012 - Tuberculous and non-tuberculous mycobacterial infections: epidemiology I Year: 2012
The treatment of tuberculosis and application of HAART (highly active anti retroviral treatment) in HIV positive patients Source: Annual Congress 2005 - Challenges in the management of pulmonary tuberculosis: a continuous clinical problem Year: 2005
Surfactant protein D (SPD) like marker of effectiveness ofphosphatidylcholine treatment outcomes in patients (pts) with community acquired pneumonia (CAP) Source: International Congress 2015 – Healthcare organisation and appropriateness in lung disorders Year: 2015
A comparison of on-site versus remote physician follow up of directly observed preventive treatment (DOPT) for latent tuberculosis infection (LTBI) on completion rates Source: Annual Congress 2012 - Tuberculous and non-tuberculous mycobacterial infections: epidemiology II Year: 2012
Treatment outcomes of tuberculosis patients under directly observed therapy (DOT) for three years Source: Eur Respir J 2004; 24: Suppl. 48, 653s Year: 2004
The efficiency of moxifloxacin (MOX) in community-acquired pneumonias (CAP) treatment while the initial antibacterial therapy (IAT) was inefficient Source: Eur Respir J 2005; 26: Suppl. 49, 638s Year: 2005
Treatment patients with pulmonary tuberculosis (PT) and accompanying pathologies by DOTS strategy Source: Eur Respir J 2005; 26: Suppl. 49, 192s Year: 2005
Immunity status of community acquired pneumonia (CAP) young patients according concomitant cytomegalovirus persistence (CMVP) Source: International Congress 2019 – Host-microbe interactions in lung disease and exacerbations Year: 2019
Accompanying therapy of patients with extensive drug-resistant (xdr) lung tuberculosis Source: International Congress 2018 – Drug-resistant tuberculosis and the sequelae of pulmonary tuberculosis Year: 2018